• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Zevra Therapeutics (ZVRA)

Common Shares
Sell: $8.31|Buy: $8.45|Change: 0.21 (2.59%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Address

1180 Celebration Boulevard
Suite 103
Celebration
FL
USA
34747

Telephone

+1 212 3752665

Website

https://www.zevra.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Zevra Therapeutics Inc Third Quarter Earnings Conference Call for 20262026-11-05T16:30:00
Zevra Therapeutics Inc Third Quarter Earnings Results for 20262026-11-05T00:00:00
Zevra Therapeutics Inc Second Quarter Earnings Conference Call for 20262026-08-12T16:30:00
Zevra Therapeutics Inc Second Quarter Earnings Results for 20262026-08-12T00:00:00
Zevra Therapeutics Inc Annual General Meeting for 20262026-05-29T09:00:00
Zevra Therapeutics Inc First Quarter Earnings Conference Call for 20262026-05-13T16:30:00
Zevra Therapeutics Inc First Quarter Earnings Results for 20262026-05-13T00:00:00
Zevra Therapeutics Inc Annual Report for 20252026-03-12T00:00:00
Zevra Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-03-11T16:30:00
Zevra Therapeutics Inc Fourth Quarter Earnings Results for 20252026-03-11T00:00:00

Previous key dates

NameKey Date
Guggenheim's 2(nd) Annual Healthcare Innovation Conference2025-11-12T11:30:00
Zevra Therapeutics Inc Third Quarter Earnings Conference Call for 20252025-11-05T16:30:00
Zevra Therapeutics Inc Third Quarter Earnings Result for 20252025-11-05T00:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-08T10:00:00
Cantor Global Healthcare Conference2025-09-03T11:30:00
Canaccord Genuity 45th Annual Growth Conference2025-08-13T13:00:00
Zevra Therapeutics Inc Second Quarter Earnings Conference Call for 20252025-08-12T16:30:00
Zevra Therapeutics Inc Second Quarter Earnings Result for 20252025-08-12T00:00:00
Zevra Therapeutics Inc Annual General Meeting for 20252025-05-29T09:00:00
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ2025-05-20T12:30:00
Zevra Therapeutics Inc First Quarter Earnings Conference Call for 20252025-05-13T16:30:00
Zevra Therapeutics Inc First Quarter Earnings Result for 20252025-05-13T00:00:00
Citizens Life Science Conference2025-05-07T11:30:00
37th Annual ROTH Conference on Monday2025-03-17T13:00:00
Zevra Therapeutics Inc Annual Report for 20242025-03-12T00:00:00
Zevra Therapeutics Inc Fourth Quarter Earnings Conference Call for 20242025-03-11T16:30:00
Zevra Therapeutics Inc Fourth Quarter Earnings Result for 20242025-03-11T00:00:00
TD Cowen 45th Annual Health Care Conference2025-03-05T10:30:00
Oppenheimer & Co. 35th Annual Healthcare Life Sciences Conference2025-02-12T15:20:00
Guggenheim Securities SMID Cap Biotechnology Conference2025-02-05T14:30:00
Piper Sandler 36th Annual Healthcare Conference2024-12-04T10:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.